Review





Similar Products

human pca cell lines  (ATCC)
99
ATCC human pca cell lines
Human Pca Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/pmc13090603-28-1-9
Average 99 stars, based on 1 article reviews
human pca cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
cell culture human pca cell lines  (ATCC)
99
ATCC cell culture human pca cell lines
Cell Culture Human Pca Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/pm42265556-62-0-30
Average 99 stars, based on 1 article reviews
cell culture human pca cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
pca cell lines  (ATCC)
99
ATCC pca cell lines
Pca Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/pmc13101708-35-0-9
Average 99 stars, based on 1 article reviews
pca cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
du145 cells  (ATCC)
99
ATCC du145 cells
Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative <t>DU145</t> cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Du145 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/bio_rxiv__64898__2026__05__26__727474-105-6-18
Average 99 stars, based on 1 article reviews
du145 cells - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
cell lines  (ATCC)
99
ATCC cell lines
Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative <t>DU145</t> cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/pm42192547-160-6-16
Average 99 stars, based on 1 article reviews
cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
human prostate cancer cell lines pc 3  (ATCC)
99
ATCC human prostate cancer cell lines pc 3
Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative <t>DU145</t> cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Human Prostate Cancer Cell Lines Pc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/pm42183963-96-20-33
Average 99 stars, based on 1 article reviews
human prostate cancer cell lines pc 3 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
human prostate carcinoma cell line du145  (ATCC)
99
ATCC human prostate carcinoma cell line du145
Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative <t>DU145</t> cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Human Prostate Carcinoma Cell Line Du145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/du-145+cells/DU+145/pm42126812-145-14-30
Average 99 stars, based on 1 article reviews
human prostate carcinoma cell line du145 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.

Journal: bioRxiv

Article Title: A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer

doi: 10.64898/2026.05.26.727474

Figure Lengend Snippet: Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.

Article Snippet: 22Rv1 cells, LNCaP cells, VCaP cells, DU145 cells, A549 cells, MDA-231 cells and HeLa cells were purchased from ATCC and frozen after less than 5 passages.

Techniques: MTT Assay, Control